FHIR IG analytics

Resources that use this resource

No resources found

Resources that this resource uses

Narrative

Note: links and images are rebased to the (stated) source

Source1

{
  "resourceType": "ConceptMap",
  "id": "mii-cm-onko-atc-transitions-2022",
  "meta": {
    "extension": [
      {
        "url": "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-license",
        "valueCode": "CC-BY-4.0"
      },
      {
        "extension": [
          {
            "url": "packageId",
            "valueId": "de.medizininformatikinitiative.kerndatensatz.onkologie"
          },
          {
            "url": "version",
            "valueString": "2027.0.0-ballot.1"
          },
          {
            "url": "uri",
            "valueUri": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko"
          }
        ],
        "url": "http://hl7.org/fhir/StructureDefinition/package-source"
      }
    ],
    "profile": [
      "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-shareableconceptmap",
      "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-publishableconceptmap"
    ]
  },
  "text": {
    "status": "generated",
    "div": "<!-- snip (see above) -->"
  },
  "extension": [
    {
      "url": "http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability",
      "valueCode": "shareable"
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability",
      "valueCode": "publishable"
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/artifact-versionPolicy",
      "valueCodeableConcept": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/artifact-version-policy-codes",
            "code": "package",
            "display": "Package"
          }
        ]
      }
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/resource-approvalDate",
      "valueDate": "2026-09-15"
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/artifact-topic",
      "valueCodeableConcept": {
        "coding": [
          {
            "system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "code": "C3262"
          }
        ]
      }
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/artifact-author",
      "valueContactDetail": {
        "telecom": [
          {
            "system": "email",
            "value": "thomas.debertshaeuser@charite.de"
          }
        ]
      }
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/artifact-editor",
      "valueContactDetail": {
        "name": "Taskforce Core Data Set"
      }
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/artifact-reviewer",
      "valueContactDetail": {
        "name": "Interoperability Working Group",
        "telecom": [
          {
            "system": "url",
            "value": "https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group"
          }
        ]
      }
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/artifact-reviewer",
      "valueContactDetail": {
        "name": "National Steering Committee",
        "telecom": [
          {
            "system": "url",
            "value": "https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee"
          }
        ]
      }
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/artifact-endorser",
      "valueContactDetail": {
        "name": "Interoperability Working Group",
        "telecom": [
          {
            "system": "url",
            "value": "https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group"
          }
        ]
      }
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/artifact-endorser",
      "valueContactDetail": {
        "name": "National Steering Committee",
        "telecom": [
          {
            "system": "url",
            "value": "https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee"
          }
        ]
      }
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/artifact-versionAlgorithm",
      "valueCoding": {
        "system": "http://hl7.org/fhir/version-algorithm",
        "code": "semver",
        "display": "SemVer"
      }
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/resource-effectivePeriod",
      "valuePeriod": {
        "start": "2027"
      }
    }
  ],
  "url": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ConceptMap/mii-cm-onko-atc-transitions-2022",
  "version": "2027.0.0-ballot.1",
  "name": "MII_CM_Onko_ATC_Transitions_2022",
  "title": "MII CM Onko ATC Code Changes 2021 to 2022",
  "status": "active",
  "experimental": false,
  "date": "2026-08-25",
  "publisher": "Medizininformatik Initiative",
  "contact": [
    {
      "name": "Medizininformatik Initiative",
      "telecom": [
        {
          "system": "url",
          "value": "https://www.medizininformatik-initiative.de/"
        }
      ]
    }
  ],
  "description": "Diese ConceptMap dokumentiert die ATC-Code-Änderungen von 2021 zu 2022. In diesem Jahr erfolgte die größte Reklassifikation der onkologischen ATC-Systematik: die monoklonalen Antikörper wurden aus der Sammelgruppe L01XC in die neue, nach Zielstruktur gegliederte Gruppe L01F überführt.",
  "jurisdiction": [
    {
      "coding": [
        {
          "system": "urn:iso:std:iso:3166",
          "code": "DE",
          "display": "Germany"
        }
      ]
    }
  ],
  "purpose": "Migration von ATC-Codes für monoklonale Antikörper, die 2022 von L01XC nach L01F umkodiert wurden.",
  "sourceCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2021",
  "targetCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2022",
  "group": [
    {
      "source": "http://fhir.de/CodeSystem/bfarm/atc",
      "target": "http://fhir.de/CodeSystem/bfarm/atc",
      "element": [
        {
          "code": "L01XC02",
          "display": "Rituximab",
          "target": [
            {
              "code": "L01FA01",
              "display": "Rituximab",
              "equivalence": "equivalent",
              "comment": "Reklassifizierung zu CD20-Inhibitoren"
            }
          ]
        },
        {
          "code": "L01XC15",
          "display": "Obinutuzumab",
          "target": [
            {
              "code": "L01FA03",
              "display": "Obinutuzumab",
              "equivalence": "equivalent",
              "comment": "Reklassifizierung zu CD20-Inhibitoren"
            }
          ]
        },
        {
          "code": "L01XC26",
          "display": "Inotuzumab ozogamicin",
          "target": [
            {
              "code": "L01FB01",
              "display": "Inotuzumab ozogamicin",
              "equivalence": "equivalent",
              "comment": "Reklassifizierung zu CD22-Inhibitoren"
            }
          ]
        },
        {
          "code": "L01XC24",
          "display": "Daratumumab",
          "target": [
            {
              "code": "L01FC01",
              "display": "Daratumumab",
              "equivalence": "equivalent",
              "comment": "Reklassifizierung zu CD38-Inhibitoren"
            }
          ]
        },
        {
          "code": "L01XC03",
          "display": "Trastuzumab",
          "target": [
            {
              "code": "L01FD01",
              "display": "Trastuzumab",
              "equivalence": "equivalent",
              "comment": "Reklassifizierung zu HER2-Inhibitoren"
            }
          ]
        },
        {
          "code": "L01XC13",
          "display": "Pertuzumab",
          "target": [
            {
              "code": "L01FD02",
              "display": "Pertuzumab",
              "equivalence": "equivalent",
              "comment": "Reklassifizierung zu HER2-Inhibitoren"
            }
          ]
        },
        {
          "code": "L01XC14",
          "display": "Trastuzumab emtansin",
          "target": [
            {
              "code": "L01FD03",
              "display": "Trastuzumab emtansin",
              "equivalence": "equivalent",
              "comment": "Reklassifizierung zu HER2-Inhibitoren"
            }
          ]
        },
        {
          "code": "L01XC06",
          "display": "Cetuximab",
          "target": [
            {
              "code": "L01FE01",
              "display": "Cetuximab",
              "equivalence": "equivalent",
              "comment": "Reklassifizierung zu EGFR-Inhibitoren"
            }
          ]
        },
        {
          "code": "L01XC08",
          "display": "Panitumumab",
          "target": [
            {
              "code": "L01FE02",
              "display": "Panitumumab",
              "equivalence": "equivalent",
              "comment": "Reklassifizierung zu EGFR-Inhibitoren"
            }
          ]
        },
        {
          "code": "L01XC17",
          "display": "Nivolumab",
          "target": [
            {
              "code": "L01FF01",
              "display": "Nivolumab",
              "equivalence": "equivalent",
              "comment": "Reklassifizierung zu PD-1-/PD-L1-Inhibitoren"
            }
          ]
        },
        {
          "code": "L01XC18",
          "display": "Pembrolizumab",
          "target": [
            {
              "code": "L01FF02",
              "display": "Pembrolizumab",
              "equivalence": "equivalent",
              "comment": "Reklassifizierung zu PD-1-/PD-L1-Inhibitoren"
            }
          ]
        },
        {
          "code": "L01XC28",
          "display": "Durvalumab",
          "target": [
            {
              "code": "L01FF03",
              "display": "Durvalumab",
              "equivalence": "equivalent",
              "comment": "Reklassifizierung zu PD-1-/PD-L1-Inhibitoren"
            }
          ]
        },
        {
          "code": "L01XC31",
          "display": "Avelumab",
          "target": [
            {
              "code": "L01FF04",
              "display": "Avelumab",
              "equivalence": "equivalent",
              "comment": "Reklassifizierung zu PD-1-/PD-L1-Inhibitoren"
            }
          ]
        },
        {
          "code": "L01XC32",
          "display": "Atezolizumab",
          "target": [
            {
              "code": "L01FF05",
              "display": "Atezolizumab",
              "equivalence": "equivalent",
              "comment": "Reklassifizierung zu PD-1-/PD-L1-Inhibitoren"
            }
          ]
        },
        {
          "code": "L01XC07",
          "display": "Bevacizumab",
          "target": [
            {
              "code": "L01FG01",
              "display": "Bevacizumab",
              "equivalence": "equivalent",
              "comment": "Reklassifizierung zu VEGF-/VEGFR-Inhibitoren"
            }
          ]
        },
        {
          "code": "L01XC21",
          "display": "Ramucirumab",
          "target": [
            {
              "code": "L01FG02",
              "display": "Ramucirumab",
              "equivalence": "equivalent",
              "comment": "Reklassifizierung zu VEGF-/VEGFR-Inhibitoren"
            }
          ]
        },
        {
          "code": "L01XC11",
          "display": "Ipilimumab",
          "target": [
            {
              "code": "L01FX04",
              "display": "Ipilimumab",
              "equivalence": "equivalent",
              "comment": "Reklassifizierung zu andere monoklonale Antikörper"
            }
          ]
        },
        {
          "code": "L01XC12",
          "display": "Brentuximab vedotin",
          "target": [
            {
              "code": "L01FX05",
              "display": "Brentuximab vedotin",
              "equivalence": "equivalent",
              "comment": "Reklassifizierung zu andere monoklonale Antikörper"
            }
          ]
        },
        {
          "code": "L01XC19",
          "display": "Blinatumomab",
          "target": [
            {
              "code": "L01FX07",
              "display": "Blinatumomab",
              "equivalence": "equivalent",
              "comment": "Reklassifizierung zu andere monoklonale Antikörper"
            }
          ]
        },
        {
          "code": "L01XC27",
          "display": "Olaratumab",
          "target": [
            {
              "code": "L01FX10",
              "display": "Olaratumab",
              "equivalence": "equivalent",
              "comment": "Reklassifizierung zu andere monoklonale Antikörper"
            }
          ]
        }
      ]
    }
  ]
}